High Expression of CARM1 Inhibits Lung Cancer Progression by Targeting TP53 by Regulating CTNNB1

Overview

Journal Lung

Specialty Pulmonary Medicine

Date 2020 Feb 9

PMID 32034480

Citations 10

Authors

Bing Hu

Xin Li

Ling Chen

Zhongliang Liu

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the role of CARM1 in lung cancer (LC) and its relationship with TP53 and CTNNB1.

Methods: Lung cells H1299 and PC14 were randomly divided into six groups: ov-H1299, si-H1299, ov-PC14, si-PC14, Con-H1299, and Con-PC14. Transwell assay, plate clone formation assay, and flow cytometry were used to determine the migration, clone formation capacity, and apoptosis situation of LC cells in the six groups, respectively. Western blot assay was used to determine the protein expression of CARM1, TP53, and CTNNB1 in the six groups. CHIP assay was applied to analyze the combined characteristics of JUN and TP53 promoter. Co-immunoprecipitation was used to analyze the interaction between TP53 and CARM1/CTNNB1. Cox proportional hazard regression model was used to analyze the relevance between the expression of CARM1 and clinicopathological information of the patient. Kaplan-Meier plot was used to determine the relevance between CARM1 and patient survival.

Results: High expression of CARM1 inhibits the migration and proliferation of LC cells and promoted the apoptosis of LC cell. Overexpression of CARM1 promotes the expression of CARM1 and TP53, while decreases CTNNB1 expression. CARM1 supplementation of H1299 cells induced JUN aggregation on the TP53 promoter. TP53 and CARM1 protein/TP53 and CTNNB1 protein in H1299 cells were immunoprecipitated together. High expression of CARM1was negatively correlated with the degree of tumor metastasis. The survival period of patients with high expression CARM1 was greater than that of low expression.

Conclusion: Overexpression of CARM1 may inhibit the progression of LC by targeting TP53 via regulation CTNNB1.

Citing Articles

Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p.

Huang G, Liu Y, Li L, Li B, Jiang T, Cao Y Front Oncol. 2025; 14:1508715.

PMID: 39759146 PMC: 11697600. DOI: 10.3389/fonc.2024.1508715.

Dysregulation of arginine methylation in tumorigenesis.

Li X, Song Y, Mu W, Hou X, Ba T, Ji S Front Mol Biosci. 2024; 11:1420365.

PMID: 38911125 PMC: 11190088. DOI: 10.3389/fmolb.2024.1420365.

Integrating UPLC-Q-Orbitrap MS with serum pharmacochemistry network and experimental verification to explore the pharmacological mechanisms of rhizoma et radix against sepsis-induced acute lung injury.

Gao H, Yuan Z, Liang H, Liu Y Front Pharmacol. 2024; 15:1261772.

PMID: 38584603 PMC: 10995315. DOI: 10.3389/fphar.2024.1261772.

Inhibition of CARM1 suppresses proliferation of multiple myeloma cells through activation of p53 signaling pathway.

Yang L, Ma L, Gong Q, Chen J, Huang Q Mol Biol Rep. 2023; 50(9):7457-7469.

PMID: 37477799 PMC: 10460731. DOI: 10.1007/s11033-023-08645-5.

Centipeda minima active components and mechanisms in lung cancer.

Gao C, Pan H, Ma F, Zhang Z, Zhao Z, Song J BMC Complement Med Ther. 2023; 23(1):89.

PMID: 36959600 PMC: 10035269. DOI: 10.1186/s12906-023-03915-y.

References

Chen D, Ma H, Hong H, Koh S, Huang S, Schurter B . Regulation of transcription by a protein methyltransferase. Science. 1999; 284(5423):2174-7. DOI: 10.1126/science.284.5423.2174. View

Cho S, Park C, Na D, Han J, Lee J, Park O . High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. Exp Mol Med. 2017; 49(4):e317. PMC: 5420801. DOI: 10.1038/emm.2017.9. View

El Messaoudi S, Fabbrizio E, Rodriguez C, Chuchana P, Fauquier L, Cheng D . Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. Proc Natl Acad Sci U S A. 2006; 103(36):13351-6. PMC: 1569167. DOI: 10.1073/pnas.0605692103. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Green D, Kroemer G . Cytoplasmic functions of the tumour suppressor p53. Nature. 2009; 458(7242):1127-30. PMC: 2814168. DOI: 10.1038/nature07986. View

Saccani S, Natoli G . Dynamic changes in histone H3 Lys 9 methylation occurring at tightly regulated inducible inflammatory genes. Genes Dev. 2002; 16(17):2219-24. PMC: 186673. DOI: 10.1101/gad.232502. View

Marchevsky A, Gal A, Shah S, Koss M . Morphometry confirms the presence of considerable nuclear size overlap between "small cells" and "large cells" in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol. 2001; 116(4):466-72. DOI: 10.1309/H40B-8W14-4Q47-03EP. View

Shishkova E, Zeng H, Liu F, Kwiecien N, Hebert A, Coon J . Global mapping of CARM1 substrates defines enzyme specificity and substrate recognition. Nat Commun. 2017; 8:15571. PMC: 5458078. DOI: 10.1038/ncomms15571. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

10.

Li P, Yao H, Zhang Z, Li M, Luo Y, Thompson P . Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol. 2008; 28(15):4745-58. PMC: 2493360. DOI: 10.1128/MCB.01747-07. View

11.

Miranda T, Miranda M, Frankel A, Clarke S . PRMT7 is a member of the protein arginine methyltransferase family with a distinct substrate specificity. J Biol Chem. 2004; 279(22):22902-7. DOI: 10.1074/jbc.M312904200. View

12.

An W, Kim J, Roeder R . Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell. 2004; 117(6):735-48. DOI: 10.1016/j.cell.2004.05.009. View

13.

Pfister N, Prives C . Chromatin dysregulation by mutant p53. Oncotarget. 2016; 7(21):29875-6. PMC: 5058647. DOI: 10.18632/oncotarget.7922. View

14.

Bulzico D, Torres D, Moura Ferreira G, Pires B, Faria P, Hassan R . A Novel TP53 Mutation Associated with TWIST1 and SIP1 Expression in an Aggressive Adrenocortical Carcinoma. Endocr Pathol. 2017; 28(4):326-331. DOI: 10.1007/s12022-017-9482-7. View

15.

Fassina A, Cappellesso R, Fassan M . Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling. Chest. 2011; 140(5):1305-1311. DOI: 10.1378/chest.11-0708. View

16.

Lee Y, Koh S, Zhang X, Cheng X, Stallcup M . Synergy among nuclear receptor coactivators: selective requirement for protein methyltransferase and acetyltransferase activities. Mol Cell Biol. 2002; 22(11):3621-32. PMC: 133819. DOI: 10.1128/MCB.22.11.3621-3632.2002. View

17.

Petitjean A, Achatz M, Borresen-Dale A, Hainaut P, Olivier M . TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007; 26(15):2157-65. DOI: 10.1038/sj.onc.1210302. View

18.

Cheng H, Qin Y, Fan H, Su P, Zhang X, Zhang H . Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes. Diagn Pathol. 2013; 8:129. PMC: 3766166. DOI: 10.1186/1746-1596-8-129. View

19.

Elakoum R, Gauchotte G, Oussalah A, Wissler M, Clement-Duchene C, Vignaud J . CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features. Biochimie. 2013; 97:210-8. DOI: 10.1016/j.biochi.2013.10.021. View